FIGURE 2.
Behavioral results for Exp 1 (A) and Exp 2 (B). (A) In Exp 1 (24 IU administration), OXT significantly increased EED ratings. To allow for a better comparison with Exp 2, effects of OXT on positive and negative EED trials, as well as on EEI are also shown. (B) In Exp 2 (40 IU administration), OXT increased both EED and EEI ratings; an effect of OXT on negative EED drove the significant treatment by valence interaction. (∗P < 0.05).